Robin Kate Kelley

32PUBLICATIONS
223CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jun 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Dec 29, 2025
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis

|Dec 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials.

Fen Saj, Felicity K Namayanja, Lianchun Xiao

|Dec 08, 2025
T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.

Robin K Kelley, Young Lee, James Conway

|Aug 08, 2025
Immunotherapy and Cirrhosis: Expanding Child-Pugh Boundaries in Liver Cancer.

Michael Li, Robin K Kelley

Pageof 6

Frequent Collaborators

9 joint publications

Ghassan K Abou-Alfa

5 joint publications

John D Gordan

4 joint publications

Ann-Lii Cheng

4 joint publications

Milind M Javle